(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
25 May 2023 (25.05.2023)

WIPO | PCT

(10) International Publication Number
WO 2023/089527 A1

(51) International Patent Classification:
A61P 35/00 (2006.01) *A61K 31/4985* (2006.01)
A61K 31/496 (2006.01) *A61K 39/395* (2006.01)
A61K 31/498 (2006.01)

(21) International Application Number:
PCT/IB2022/061095

(22) International Filing Date:
17 November 2022 (17.11.2022)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
63/280,682 18 November 2021 (18.11.2021) US

(71) Applicants: **ASTRAZENECA UK LIMITED** [GB/GB]; 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge CB2 0AA (GB). **DAIICHI SANKYO COMPANY, LIMITED** [JP/JP]; 3-5-1, Nihonbashi Honcho, Chuo-ku, Tokyo 103-8426 (JP).

(72) Inventors: **SUNG, Matthew Simon**; c/o AstraZeneca Pharmaceuticals LP, 1800 Concord Pike, Wilmington, Delaware P.O. Box 15437 (US). **METTETAL II, Jerome Thomas**; c/o AstraZeneca Pharmaceuticals LP, 1800 Concord Pike, Wilmington, Delaware P.O. Box 15437 (US). **LEO, Elisabetta**; c/o AstraZeneca UK Limited, 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge CB2 0AA (GB). **WALLEZ, Yann**; c/o AstraZeneca UK Limited, 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge CB2 0AA (GB). **PROIA, Theresa Angela**; c/o AstraZeneca Pharmaceuticals LP, 1800 Concord Pike, Wilmington, Delaware P.O. Box 15437 (US).

(74) Agent: **ANGUS, Fairbairn**; Marks & Clerk LLP, 15 Fetter Lane, London EC4A 1BW (GB).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:
— *with international search report (Art. 21(3))*
— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*
— *with sequence listing part of description (Rule 5.2(a))*

(54) Title: COMBINATION OF ANTIBODY-DRUG CONJUGATE AND PARP1 SELECTIVE INHIBITOR



(II)

(57) Abstract: A pharmaceutical product for administration of an anti-TROP2 antibody-drug conjugate in combination with a PARP1 selective inhibitor is provided. The anti-TROP2 antibody-drug conjugate is an antibody-drug conjugate in which a drug-linker represented by the following formula (wherein A represents the connecting position to an anti-TROP2 antibody) is conjugated to an anti-TROP2 antibody via a thioether bond. Also provided is a therapeutic use and method wherein the anti-TROP2 antibody-drug conjugate and the PARP1 selective inhibitor are administered in combination to a subject : Formula (II)

WO 2023/089527 A1